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Background. Tianjiu therapy has established efficacy against chronic asthma with related symptoms or the medication need during
asthma attack. This study aimed to explore the optimal duration of Tianjiu therapy for asthma. Methods. This study was a self-
comparison-to-the-baseline study, which comparing treatment with Tianjiu therapy for 1 year and 2 years in the same 102 chronic
asthma patients. Totally 6 sessions of Tianjiu treatment were provided, 3 sessions in a year as a course of treatment and totally two
years treatment.The primary endpoint was the number of asthma related symptoms which frequently appeared in asthma patients
and the frequency of bronchodilator used during asthma attack.Results.The frequency of bronchodilator used during asthma attack
significantly improved (𝜒2 = 46.276, 𝑃 = 0.000). But the number of asthma related symptoms which frequently appeared in asthma
patients added by 1.38 points (95% CI, 0.25 to 2.51), 2.93 ± 0.41 in 1-year group and 4.31 ± 0.41 in the 2-years group (𝑃 < 0.05).
Conclusions.The effect of 2 years Tianjiu therapy was not as effective as 1 year such treatment for asthma, but the second year Tianjiu
therapy was still needed because it has a role to consolidate the curative effect of Tianjiu therapy for asthma.
1. Introduction
Asthma is one of the most common chronic diseases in the
world. Currently, 𝛽-agonist as the first-line drug in treating
acute asthma attack and glucocorticoids is still used widely to
treat chronic asthma [1]. From the perspective of immunol-
ogy, asthma is a systemic allergic disease with immune
disturbance. Allergic airway inflammation is only a local
show, and inhaled glucocorticoids also only pay attention to
the local anti-inflammatory therapy while overlooking the
systemic immune dysfunction in asthma patients. Hence,
current therapy for asthma is still imperfect; it needs us to
keep improving the therapy for asthma, and immunotherapy
is likely to be one of the important ways to improve asthma
therapy [2]. Traditional Chinese medicine (TCM) has a long
history of treating asthma and it claimed that the mechanism
of asthma mainly lies in two aspects: one is “deficiency in
origin” and another is “enrichment in symptom.” The saying
of “deficiency in origin” is similar to “systemic immune
dysfunction,” and “enrichment in symptom” is similar to
“allergic airway inflammation.” TCM pays more attention to
the “preventive treatment of disease,” which means conduct
prevention treatment for asthma patients when there is no
asthma attack. Tianjiu Therapy in Sanfu Days is a classic
prevention treatment for asthma. SanfuDaysmeans the three
hottest days in a yearwhich are calculated by ancient calendar.
Both Positive-qi in human body and nature are in a most
exuberant status in Sanfu Days, so Sanfu Days is a good
time for cold-insufficiency patients to tonic Positive-qi. As a
result, patients can have a strong body-resistance to against
exogenous pathogen because they have already accumulative
enough Positive-qi inside. Just as Chinese medicine said:
“when there is sufficient Positive-qi inside, the Pathogenic-
qi has no way to invade the health body.” Tianjiu Therapy
means applying herbs patches on special acupoints in order
to stimulate skin to form blisters, hyperemia, and even
suppuration. As a result, Sanfu Tianjiu Therapy can attain
the goal of strengthening Yang-qi, removing cold pathogen,
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and enhancing body resistance through the combination
effect of drug infiltration absorption, acupoints stimulation,
and time effect. Sanfu Tianjiu Therapy for asthma aims to
improve the body immunity which in turn can get a purpose
of preventing and reducing respiratory viral or bacterial
infection, reducing airway inflammation injury, and reduc-
ing airway hyperresponsiveness which in turn reduces the
times of asthma attacks [3–12]. Tianjiu Therapy substantially
improves asthma control level and the quality of life in
patients with asthma and is used widely in Mainland China
as an adjuvant setting [3–12]. We have already conducted
an initial trial which compared 1 year of Tianjiu treatment
with a placebo control group. In that study, it was found that
Tianjiu Therapy can really reduce the need for medications
to control asthma, improved the quality of participants’ life,
and significantly reduced the level of asthma. Previous study
has preliminary confirmed the effect of Tianjiu Therapy in
Sanfu Days for asthma, while the optimal treatment duration
is still unknown. Hence this study was conducted to compare
the different effect of 2-year TianjiuTherapy with 1-year such
treatment in asthma patients.
2. Methods
2.1. Enrollment Criteria. This study was a self-control and
clinical efficacy observation trial in 102 Hong Kong citizens
(above 13 years of age) with chronic asthma. Participants need
to provide physician’s diagnosis of asthma or documentation
of asthma-related symptoms preceding study visit. Besides,
all participants should provide evidence of asthma attack
as indicated by hospitalization or unscheduled urgent care
twelve months before study entry. In addition, all patients
were required to meet the following inclusion criteria: cough
(worse at night), difficulty in breathing, chest tightness,
awakening the patient, and symptoms occurring or worsen-
ing with exercise or at night; episodic symptoms of airflow
obstruction, viral infections, strong emotions, and changes in
weather. Patients would be assessed ineligibility according to
one ormore of the following exclusion criteria: severe cardiac
and pulmonary diseases; fever, pharyngitis, acute asthma
attack, and pregnancy. Diabetes mellitus, tuberculosis, and
hypersensitive skin condition were also forming the excluded
reasons. Additionally, allergy to topical medication, severe
heart diseases, keloid, bleeding disorders or participants with
pacemaker will also be excluded.
This study was approved by the Institutional Review
Board of the University of Hong Kong/Hospital Authority
Hong KongWest Cluster (HKU/HA HKW IRB) with coding
UW 13-316. All participants were informed about this study
and written informed consent was obtained from every
patient or patient’s legal guardian or the patient’s parent.
2.2. Study Design. In this study, participants from 2010 to
2013 who totally receive two courses of Tianjiu Therapy (one
course means completing three-time Tianjiu Therapy in a
year, so two-course treatment needs at least two years and six-
time Tianjiu Therapy) will constitute study subjects for final
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Figure 1: Acupoints.
analysis. For example, patients who have already received 1-
course TianjiuTherapy in 2010 need to receive another course
treatment in 2011 or 2012 or 2013. Patients fromplacebo group
in 2010 still need to receive other 2-course treatment in the
following three years. As a result, 102 patients who totally
received two-course treatment were included for the final
analysis. These 102 patients must complete two-course pre-
assessment and postassessment which means that they have
completed data in four time points. Among these 102 patients,
there were 68 continuous participants (attended in 2010 and
2011, 2011 and 2012, or 2012 and 2013) plus 34 discontinuous
participants (attended in 2010 and 2012, 2010 and 2013, or
2011 and 2013). This study conducted a subgroup analysis
for continuous group and discontinuous group, but nothing
different was found in most of the outcome measurements.
Hence, this study combined continuous participants with
discontinuous participants as study subjects.
Each year Asthma Control Test (ACT), self-made ques-
tionnaire, and pulmonary function will be assessed for
participants before treatment and after treatment. Also three-
time Tianjiu Therapy with 2-hour duration in a year was
conducted for all participants from 2010 to 2013 and every
time Tianjiu Therapy was conducted in Sanfu Days. In other
words, eligibility patients participated in a certain year study
then that year’s three treatments and pre and post assessment
were conducted for them. The three treatment times from
2010 to 2013 were July 19, July 29, and August 8, 2010; July
14, July 24, and August 13, 2011; July 18, July 28, and August 7,
2012; July 13, July 23, and August 12, 2013.
Eleven acupoints will be applied by Tianjiu patches: BL13
(both sides), BL23 (both sides), BL43 (both sides), EX-B1
(both sides), Du14, Du12, and Du4 (Figure 1).
One patch was applied on one acupoint and every patch
weighted 2 grams (Figure 2).
The formula of Tianjiu patch was a combination of the
formula frequency used in clinical trials and the record in
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Figure 2: Tianjiu patch.
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Figure 3: Tianjiu Therapy schematic diagram.
“Zhang Shi Yi Tong.” The final formula used consisted of
Sinapis alba, Radix Corydalis Yanhusuo, processed Euphor-
bia kansui, Asari Herba cum Radice, Ephedrae Herba, pro-
cessed Radix Aconiti Praeparata, Cinnamomum cassia, and
Eugenia caryophyllata. The ratio of selected herbal was
2 : 1 : 1 : 1 : 1 : 1 : 1 : 1 and all this herbal powder will be mixed
together with ginger juice. Finally, approximately 4 cm× 4 cm
hypoallergenic tape (3MMicropore Tape 1535-3) will be used
to stick Tianjiu patches on skin after the patch was applying
on acupoints (Figure 3).
2.3. Outcome Measures. The primary outcome was the num-
ber of asthma-related symptoms which frequently appeared
in asthma patients and the frequency of bronchodilator used
during asthma attack. Other outcomes included the number
of dayswith asthma-related symptoms in 1month before visit;
spirometric measurements; asthma-related health care use
and the score on the ACT. Scores on the ACT range from 5 to
25, with scores of 20 or more indicating disease control and
3 points are the minimally important difference for the ACT
score [13].
2.4. Statistical Analysis. Continuous variables in this study
from 1st year baseline to 2nd year posttreatment were exam-
ined using a linear mixed-effects model with time as fixed
effects. There were totally four time points in this linear
mixed-effects model: 1st year baseline as the 1st time point,
1st year posttreatment as the 2nd time point, 2nd year baseline
as the 3rd time point, and 2nd year posttreatment as the 4th
time point. The continuous variables included the score of
ACT, the number of asthma-related subhealthy symptoms,
the number of days with asthma-related symptoms, and
lung function: FEV and FEV
1
/FVC (%). All analysis was
conducted for the same 102 people. Generalized estimated
equation (GEE) analysis was performed for the frequency
of bronchodilator used during asthma attack and asthma-
related health care used during asthma attack in order to
repeat measures in different time points. Descriptive analysis
was conducted for the percentage of patients with twenty-
three asthma-related symptoms which frequently appeared
in asthma patients. Statistical analyses were performed with
the Statistical Package for the Social Sciences (SPSS) software
program (version 19) for windows XP.
3. Results
From June 2010 through July 2010, 323 patients were recruited
in 2010 and finally 242 patients completed treatment. 274
patients were recruited as study subjects in 2011, of which
84 participants were from 2010 Tianjiu Therapy group, 82
were from 2010 placebo group, and 108 were new recruited
subjects. During the treatment period and postassessment
in 2011, 104 patients did not complete all parts. As a result,
170 participants completed all treatments and postassessment
in 2011. Totally 132 patients completed all treatments and
pre- and postassessments in 2012, and 150 patients lastly
completed preassessments, postassessments, and three-time
TianjiuTherapy in 2013. Patients would be ineligible for final
statistical analysis due to the incomplete data. The cause
of incomplete data included incomplete treatments, during
treatment period participants losing contact, illnesses, preg-
nancy, asthma exacerbation, inability to participate timely,
refusing to participate, or incomplete questionnaires, ACT, or
lung function test.The patients can be included for final anal-
ysis only when they have four time points’ data (1st year pre-
and postassessments, 2nd year pre- and postassessments).
Overall, from 2010 to 2013, patients who received two-course
treatment were 102.
For the baseline characteristics of these 102 participants,
the average age was 50.4 years (interquartile range, 13 to
78); 53% were female (Table 1). The average number of
days on which patients had asthma-related symptoms was
9.35. Patients had a mean ACT score of 19 or less which
indicated a lack of disease control [14]. In the previous year,
22.5% patients received emergency treatments at least once
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Table 1: Baseline characteristics of study participants.
Characteristic Tianjiu Therapy(𝑁 = 102)
Age—year 50.35 ± 17.17
Gender—number (%)
Male 48 (47.1)
Female 54 (52.9)
Duration of asthma—year 20.22 ± 14.14
Asthma-related symptoms—number ofa 9.35 ± 11.90
Lung function
FEV1 1.86 ± 0.98
FEV1:FVC × 100 85.24 ± 27.76
Asthma-related health care—number (%)
≥1 Admitted to A and Eb 23 (22.5)
≥1 Hospitalization 19 (18.6)
≥1 Outpatient visit 60 (58.8)
≥1 Prescription 72 (70.6)
≥1 Buy medication 11 (10.8)
≥1 Not to be processed 10 (9.8)
The frequency of bronchodilator used
during asthma attack—number (%)
More than twice per day 25 (24.5)
Once to twice per day 38 (37.3)
2-3 times per week 5 (4.9)
Less than once per week 16 (15.7)
Never 18 (17.6)
Symptoms which frequently appeared in
asthma patients—number of symptomsc 8.20 ± 4.40
aPlus-minus values are means ± SD, unless noted otherwise. PIF denotes
peak inspiratory flow; PEF: peak expiratory flow; FEV1: forced expiratory
volume in one second; FVC: forced vital capacity.
bThe total number of symptoms which frequently appeared in asthma
patients is 23 and its scale ranges from 0 to 23.
cAccident and Emergency Departments (A and E).
which were associated with an asthma-related event, 18.6%
had been hospitalized, 58.8% went to clinic, 70.6% treated
themselves following the prescription, 10.8% buy medication
for themselves, and 9.8% did not needmedical treatment.The
mean (±SD) FEV
1
was 1.86 ± 0.98, and the mean ration of
FEV
1
to the forced vital capacity (FVC) was 85.24±27.76. For
the frequency of bronchodilator used during asthma attack,
24.5% used bronchodilator more than twice per day, 37.3%
once to twice per day, 4.9% 2-3 times per week, and 15.7%
less than once per week, and 17.6% never used bronchodilator
during asthma attack. The number of symptoms which
frequently appeared in asthma patients was 8.20 ± 4.40.
3.1. Response to Intervention. The number of symptoms
which frequently appeared in asthma patients was 2.93±0.41
in end of 1-course treatment and 4.31 ± 0.41 in end of 2-
course treatment; one course has 5.27-point reduction and
2 courses have 3.88-point reduction, respectively, comparing
with 8.20±0.41 in baseline (𝑃 < 0.05) (Figure 4 and Table 2).
8.2
2.93
7.88
4.31
Symptoms
Symptoms
1st pre 1st post 2nd pre 2nd post
Figure 4: The number of symptoms which frequently appeared in
asthma patients in 1 course and 2 courses.
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Figure 5: The frequency of bronchodilator used during asthma
attack.
But 1-course treatment reduced more points than 2-course
treatment (𝑃 < 0.05).
The frequency of bronchodilator used during asthma
attack in 2 courses was better than 1 course: 16.7% more than
twice per day in 1 course and 9.8% in 2 courses, 25.5% once
to twice per day in 1 course and 14.7% in 2 courses, 3.9% 2 to
3 times per week in 1 course and 7.8% in 2 courses, and 16.7%
less than once perweek in 1 course and 14.7% in 2 courses, and
37.3%never used it in 1 course and 52.9% in 2 courses, indicat-
ing that the frequency of bronchodilator used during asthma
attack was decreasing (Table 3 and Figure 5, 𝑃 < 0.05).
The score of ACT improved by 1.53 points (95% CI, −0.31
to 3.37) after one-course treatment (19.80) and 3.53 points
(95% CI, 1.69 to 5.37) after two courses of treatment (21.80)
(Figure 6 and Table 4). In other words, the score of ACT after
two-course treatment was better than one-course treatment
and the score of ACT showed an increasing trend (𝑃 < 0.05).
Different from the improvement like the score of ACT
and the frequency of bronchodilator used during asthma
attack, as compared with 1-year treatment, 2-year treatment
with Tianjiu increased the mean number of days on which
patients had asthma-related symptoms from 1.98 to 5.03 (𝑃 <
0.05) (Table 2 and Figure 7); even both 2-year treatment and
1-year treatment compared with baseline have a significant
improvement (𝑃 < 0.05).
No changes occurred in pulmonary function for both
1-year treatment and 2-year treatment comparing with no
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Table 3: The frequency of bronchodilator used during asthma attack—𝑛 (%).
Variable Time
1st pre 1st post 2nd pre 2nd post
More than twice per day 23 (22.5) 17 (16.7) 11 (10.8) 10 (9.8)
Once to twice per day 35 (34.3) 26 (25.5) 24 (23.5) 15 (14.7)
2-3 times per week 3 (2.9) 4 (3.9) 6 (5.9) 8 (7.8)
Less than once per week 15 (14.7) 17 (16.7) 17 (16.7) 15 (14.7)
Never 26 (25.2) 38 (37.3) 44 (43.1) 54 (52.9)
Time main effect: Wald 𝜒2 = 46.276, 𝑃 = 0.000.
Table 4: ACT score before and after treatment in 1 course and 2
courses.
1st baseline 18.27 ± 0.66
1st posttreatment 19.80 ± 0.66
2nd baseline 20.43 ± 0.66
2nd posttreatment 21.80 ± 0.66
1st posttreatment versus 1st baseline
(95% CI)/P value 1.53 (−0.31 to 3.37)
2nd posttreatment versus 1st baseline
(95% CI)/P value 3.53 (1.69 to 5.37)
###
2nd posttreatment versus 1st
posttreatment (95% CI)/P value 2.00 (0.16 to 3.84)
#
Notes: #P < 0.05; ###P < 0.001.
18.27
19.8
20.43
21.8
ACT
ACT
1st pre 1st post 2nd pre 2nd post
Figure 6: The score of ACT in 1 course and 2 courses.
treatment status. With respect to asthma-related health care
use during asthma attack, the percentage of participants
admitted to Accident and Emergency Departments (A and
E) was 1% in year 1 and 6% in 2 years; comparing with
baseline both have a significant improvement (𝑃 < 0.05).
Similarly, the proportion of patients who were hospitalized
due to asthma was 0% in 1 year and 2% in 2 years, with both
being better than no treatment (𝑃 < 0.05). The percentage of
participants who visited outpatient clinic was 9% in 1 year and
49% in 2 years; both of them have a significant improvement
in comparison with no treatment; however, the effect of 1
year was much better than 2 years (𝑃 < 0.05). The ratio
of subjects who took the previous prescription by doctors
during asthma attack was 60% in 1 year and 69% in 2 years,
and no difference occurred in both groups comparing with
no treatment (𝑃 > 0.05); the scale of patients who only need
8.44
1.98
6.94
5.03
1st pre 1st post 2nd pre 2nd post
Number of days
Number of days
Figure 7: The number of days with asthma-related symptoms in 1
year and 2 years.
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Figure 8: The proportion of participants with twenty-three symp-
toms which frequently appeared in asthma patients in 1 course and
2 courses.
to takemedication by themselves was 1% in 1 year and 8% in 2
years; 1-year treatment was better than no treatment while 2-
year treatmentwas not different frombaseline, indicating that
1-year treatment was better than 2-year treatment (𝑃 < 0.05);
last but not least, the percentage of patients who do not need
to process during asthma attack was 2% in 1 year and 10% in
2 years; 2-year treatment has nothing different from baseline,
while 1-year treatment was worse than no treatment and 2
years performed better than 1 year (𝑃 < 0.05) (Table 2).
Figure 8 showed the percentage of participants with
twenty-three symptomswhich frequently appeared in asthma
patients. Among these twenty-three symptoms, the top three
frequently occurring symptoms were as follows: easy onset
during quarter turn (67% in baseline, 16% after 1-course treat-
ment, and 25% after 2-course treatment), rapid or difficult
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breathing (75% in baseline, 39% after 1-course treatment, and
28% after 2-course treatment), and waking up with asthma
symptoms (65% in baseline, 34% after 1-course treatment, and
20% after 2-course treatment), indicating that the majority of
participants owned the lung-qi-deficiency syndromes. Nearly
all patients have a significant reduction in the twenty-three
symptoms after both 1-course Tianjiu Therapy and 2-course
such treatment. What is more, it showed that the status
of patients in the 2nd course baseline was better than 1st
course baseline which indicated that Tianjiu Therapy has a
cumulative effect after one course of treatment. Additionally,
from Figure 8, it can be found that the reduction of 1 course
was much more than 2 courses. It seems that the effect of 2
courses was not as sensitive as 1 course, regardless of the fact
that 2-course treatment still has a significant improvement
compared with 1st course baseline.
3.2. Adverse Event. The observation procedures followed
after Tianjiu Therapy were conducted in both 1 course and
2 courses. During the treatment, most patients would show
cutaneous reaction such as skin warm feeling, itching, pain,
and blisters due to the stimulation of herbal patch. All these
appearances were a normal skin reaction after Tianjiu Ther-
apy and also a key condition of Tianjiu Therapy taking effect
in the treatment of asthma. Most of them would disappear
after several hours or several days. In 1st course Tianjiu
Therapy, there were five serious adverse events reported at the
end of three-time treatment: three patients showed asthma
exacerbation, one patient showed the rash due to being aller-
gic to Tianjiu patch, and one subject tended to vomit blood
and automatically stopped after the 2nd Tianjiu Therapy,
which had confirmed that it has nothing to do with Tianjiu
Therapy. Besides, in 2nd course TianjiuTherapy, the majority
of patients also showed skin reaction after TianjiuTherapy as
that in 1st course. There were also five serious adverse events
in the 2nd course treatment: three were skin sensibility which
cannot disappear after stopping treatment even several days
later. And finally, his skin returned to normal through der-
matologist’s appropriate process. one person was caused by
the smell of paint because his house was mopping during the
treatment period; another was induced by flu. Overall, there
was nothing different between 1st course TianjiuTherapy and
2nd course Tianjiu Therapy in adverse events.
4. Discussion
In the previous study (HKCTR-1128), Tianjiu Therapy has
shown substantial improvements in the number of days with
asthma-related symptoms, the number of symptoms which
frequently appeared in asthma patients, and the medication
need after treatment. Although there was nothing different
between placebo group and Tianjiu Therapy group after the
3rd treatment immediately, the effect of Tianjiu Therapy
tended to be superior to placebo group in four-time followup.
This study was conducted to explore how long the curative
effect of Tianjiu Therapy lasts and the optimum duration
of treatment for chronic asthma based on previous finding.
This study tested the hypothesis that continuation of Tianjiu
Therapy beyond 1 course would be more effective than 1
course of such treatment. As a result, this study found
that two courses of Tianjiu Therapy showed a significant
improvement in the score of ACT as compared with 1-
course treatment and the score of ACT showed an increasing
trend. In addition, the frequency of bronchodilator used
during asthma attack in 2 courses was also superior to the
effect of 1 course. Patients’ asthma control situation in 2nd
pretreatment was better than that in the 1st pretreatment.
Which means patients’ immunity improved and kept well
after one-course Tianjiu Therapy? While, it was arbitrary to
make conclusion that the effect of 2-course Tianjiu Therapy
was superior to 1 course by only judging from the change of
the score of ACT and the bronchodilator used during asthma
attack between 1 course and 2 courses. Nevertheless, different
from the findings above, the result of the mean number
of days on which patients had asthma-related symptoms
shows no such additional benefit; the effect of 2-course
treatment was close to 1 course such treatment. Likewise,
results about the number of symptoms which frequently
appeared in asthma patients, asthma-related health care use
during asthma attack, and the percentage of participants
with symptomswhich frequently appeared in asthma patients
were not mostly different between the 1-course treatment
and 2-course such treatment. Last but not least, no changes
occurred in pulmonary function for both 1-course treatment
and 2-course treatment comparing with 1st course baseline.
Although the result was inconsistent in all outcome
measurements, it was found that the effect of 2-course Tianjiu
Therapy was less sensitive than 1 course of such treatment
for chronic asthma, but both 1-course and 2-course Tianjiu
Therapy can get a significant improvement comparing with
the situation in 1st pretreatment. And the baseline status of
the same people in the 2nd course remained well even one
year later after the first course of treatment, indicating that
the effect of Tianjiu Therapy can last for a quite long time.
For safety issue, the number of adverse events in 2nd course
treatment was nearly the same as the number in 1st course
treatment. There is no doubt that all these findings will be
beneficial for health policy makers and asthma patients.
There is a limitation of this study because this study
did not set up followups and only takes the second course’s
baseline as the followup of first course treatment. However,
Sanfu Days in every year were around July and August which
was a stable period for asthma patients, so it was easy to
produce bias without followup in asthma high incidence
and research staff cannot track the asthma control situation
of participants. Hence, it is urgent and necessary to add
followups. Table 5 showed the temperature record of 2010 to
2013.The average temperature in SanfuDays was 28.7∘C from
2010 to 2013; the average humidity was 81% from 2010 to 2013;
the average duration of sun exposure was 6.6 hours from 2010
to 2013.
5. Conclusion
Both 2-course TianjiuTherapy and one-course TianjiuTher-
apy significantly reduced the number of symptoms which
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frequently appeared in asthma patients and medication need
in participants with chronic asthma as compared with base-
line.The asthma control situation in 2nd course pretreatment
was better than 1st course pretreatment. Although the second
course Tianjiu Therapy was less sensitive than first course
TianjiuTherapy for chronic asthma, the second course treat-
ment still plays a role in consolidating the curative effect of
Tianjiu Therapy in the treatment of asthma.
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